| scholarly article | Q13442814 |
| P50 | author | R. Kiplin Guy | Q67426629 |
| Ka Hong Chan | Q101225083 | ||
| P2093 | author name string | Paul S Rennie | |
| Nathan A Lack | |||
| Artem Cherkasov | |||
| Eric LeBlanc | |||
| Peyman Tavassoli | |||
| Emma Tomlinson Guns | |||
| Clementine Feau | |||
| Peter Axerio-Cilies | |||
| Frank Q Han | |||
| P2860 | cites work | The ubiquitin-conjugating enzyme UBCH7 acts as a coactivator for steroid hormone receptors | Q24304094 |
| A surface on the androgen receptor that allosterically regulates coactivator binding | Q27648698 | ||
| ZINC--a free database of commercially available compounds for virtual screening | Q27656255 | ||
| Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening | Q27671786 | ||
| Phasercrystallographic software | Q27860930 | ||
| Refinement of macromolecular structures by the maximum-likelihood method | Q27861011 | ||
| Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy | Q28251042 | ||
| eHiTS: a new fast, exhaustive flexible ligand docking system | Q28253448 | ||
| Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function | Q31806771 | ||
| 'Inductive' charges on atoms in proteins: comparative docking with the extended steroid benchmark set and discovery of a novel SHBG ligand. | Q33227835 | ||
| Using molecular docking, 3D-QSAR, and cluster analysis for screening structurally diverse data sets of pharmacological interest | Q33371746 | ||
| Epigenetic mechanisms for progression of prostate cancer | Q33715206 | ||
| Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells | Q33951397 | ||
| In vivo amplification of the androgen receptor gene and progression of human prostate cancer | Q34314274 | ||
| Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer | Q35888364 | ||
| 20-year outcomes following conservative management of clinically localized prostate cancer | Q36115855 | ||
| Emerging therapies in castrate-resistant prostate cancer | Q37442526 | ||
| Differential transactivation by the androgen receptor in prostate cancer cells | Q38334030 | ||
| In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. | Q39899629 | ||
| Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells. | Q39980433 | ||
| Rapid, non-destructive, cell-based screening assays for agents that modulate growth, death, and androgen receptor activation in prostate cancer cells | Q40183878 | ||
| Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression | Q40213078 | ||
| Mutational analysis of the androgen receptor AF-2 (activation function 2) core domain reveals functional and mechanistic differences of conserved residues compared with other nuclear receptors | Q40847186 | ||
| Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains. | Q41528424 | ||
| Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system | Q41827081 | ||
| A high-throughput ligand competition binding assay for the androgen receptor and other nuclear receptors. | Q42118114 | ||
| A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy | Q43627769 | ||
| A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. | Q45996199 | ||
| Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. | Q47759846 | ||
| Distant metastases from prostatic carcinoma express androgen receptor protein. | Q54015736 | ||
| Hsp90 Regulates Androgen Receptor Hormone Binding Affinityin Vivo | Q62059794 | ||
| Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis | Q71634118 | ||
| Intermittent androgen suppression for prostate cancer: rationale and clinical experience | Q77686135 | ||
| Progressive docking: a hybrid QSAR/docking approach for accelerating in silico high throughput screening | Q79409344 | ||
| P2507 | corrigendum / erratum | Correction to Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor through Virtual Screening | Q106812605 |
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | drug discovery | Q1418791 |
| virtual screening | Q4112105 | ||
| P304 | page(s) | 8563-8573 | |
| P577 | publication date | 2011-11-18 | |
| P1433 | published in | Journal of Medicinal Chemistry | Q900316 |
| P1476 | title | Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening | |
| P478 | volume | 54 |
| Q99579138 | Access to highly substituted oxazoles by the reaction of α-azidochalcone with potassium thiocyanate |
| Q92702841 | Allosteric Binding Sites On Nuclear Receptors: Focus On Drug Efficacy and Selectivity |
| Q38116575 | Androgen receptor modulators: a marriage of chemistry and biology |
| Q36063723 | Androgen receptor: structure, role in prostate cancer and drug discovery |
| Q38076345 | Beyond the ligand-binding pocket: targeting alternate sites in nuclear receptors. |
| Q48219470 | Brønsted acid-catalyzed stereoselective [4+3] cycloadditions of ortho-hydroxybenzyl alcohols with N,N'-cyclic azomethine imines |
| Q53126460 | Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions. |
| Q51255354 | Catalytic cascade aldol-cyclization of tertiary ketone enolates for enantioselective synthesis of keto-esters with a C-F quaternary stereogenic center. |
| Q43211698 | Combining silver- and organocatalysis: an enantioselective sequential catalytic approach towards pyrano-annulated pyrazoles |
| Q34775572 | Constitutive activity of the androgen receptor |
| Q34993150 | Detection of persistent organic pollutants binding modes with androgen receptor ligand binding domain by docking and molecular dynamics. |
| Q42148126 | Diethyl 4-meth-oxyoxalyl-3,5-diphenyl-pyrrolidine-2,2-dicarboxyl-ate |
| Q50226984 | Drug-Discovery Pipeline for Novel Inhibitors of the Androgen Receptor |
| Q49700104 | Endocrine Disrupting Chemicals Mediated through Binding Androgen Receptor Are Associated with Diabetes Mellitus |
| Q36508759 | Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients |
| Q41889453 | IDENTIFICATION OF VDR ANTAGONISTS AMONG NUCLEAR RECEPTOR LIGANDS USING VIRTUAL SCREENING |
| Q40506281 | Identification and characterization of antibacterial compound(s) of cockroaches (Periplaneta americana). |
| Q91641819 | Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells |
| Q27689142 | Identification of a new hormone-binding site on the surface of thyroid hormone receptor |
| Q35180278 | In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α |
| Q45818620 | N-heterocyclic carbene-catalyzed highly enantioselective synthesis of substituted dihydropyranopyrazolones |
| Q52659701 | New Opportunities for Targeting the Androgen Receptor in Prostate Cancer. |
| Q35769766 | Oxidative Reactivities of 2-Furylquinolines: Ubiquitous Scaffolds in Common High-Throughput Screening Libraries. |
| Q89518885 | Principle and design of pseudo-natural products |
| Q38606010 | Recent Developments in Androgen Receptor Antagonists |
| Q34495028 | Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer. |
| Q52674189 | Selective modulation of the androgen receptor AF2 domain rescues degeneration in spinal bulbar muscular atrophy. |
| Q34249190 | Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer |
| Q37620608 | Silver(I)-Catalyzed Intramolecular Cyclizations of Epoxide-Propargylic Esters to 1,4-Oxazine Derivatives |
| Q38838223 | Structures of androgen receptor bound with ligands: advancing understanding of biological functions and drug discovery |
| Q38739244 | Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation |
| Q38114780 | Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer |
| Q38160927 | The hurdle of antiandrogen drug resistance: drug design strategies |
| Q36035011 | Transcriptional Inhibitors Identified in a 160,000-Compound Small-Molecule DUX4 Viability Screen |
Search more.